ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,827.04
      -1.54%
      US Tech 100
      20,263.20
      -1.69%
      Dow Jones
      41,938.45
      -1.63%
      Brent Oil
      79.285
      0.00%
      Bitcoin
      94,292.77
      -0.44%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Inozyme Pharma Inc (INZY) Quote

      Inozyme Pharma Inc

      Inozyme Pharma Inc (INZY)

      NASDAQ
      1.995
      -0.805
      (-28.75%)
      Closed January 11 4:00PM
      Delayed by 15 minutes
      2.08
      0.085
      (4.26%)
      After Hours: 7:18PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      2.08
      Bid
      2.01
      Ask
      2.15
      Volume
      2,190,193
      1.97 Day's Range 2.6871
      1.98 52 Week Range 7.795
      Market Cap
      133.62M
      Previous Close
      2.80
      Open
      2.652
      Last Trade
      1
      @
      2.14
      Last Trade Time
      Financial Volume
      $ 4,746,118
      VWAP
      2.167
      Average Volume (3m)
      557,546
      Shares Outstanding
      64,240,198
      Dividend Yield
      -
      PE Ratio
      -1.81
      Earnings Per Share (EPS)
      -1.11
      Revenue
      -
      Net Profit
      -71.17M

      About Inozyme Pharma Inc

      Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.inozyme.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was $2.80. Over the last year, Inozyme Pharma shares have traded in a share price range of $ 1.98 to $ 7.795.

      Inozyme Pharma currently has 64,240,198 shares outstanding. The market capitalization of Inozyme Pharma is $179.87 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -1.81.

      Ask ADVFN Intelligence (AI)

      INZY Latest News

      More News

      Form 8-K - Current report

      18 hours ago
      Edgar (US Regulatory)

      Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

      - Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and...

      18 hours ago
      GlobeNewswire Inc.

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      December 09 2024
      Edgar (US Regulatory)

      Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

      BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

      November 27 2024
      GlobeNewswire Inc.

      Inozyme Pharma to Present at Upcoming Investor Conferences

      BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

      November 11 2024
      GlobeNewswire Inc.

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 08 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 05 2024
      Edgar (US Regulatory)

      Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in...

      November 05 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      October 24 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.77-27.01754385962.853.181.985363322.91386622CS
      4-0.9-30.20134228192.983.281.985069632.92471701CS
      12-3.1-59.84555984565.185.591.985575463.11831291CS
      26-2.56-55.17241379314.646.241.983901533.88693895CS
      52-2.57-55.26881720434.657.7951.984543404.7569166CS
      156-4.36-67.7018633546.447.980.9914797554.24205713CS
      260-15.85-88.399330730617.9331.64990.9913444375.14465962CS

      INZY - Frequently Asked Questions (FAQ)

      What is the current Inozyme Pharma share price?
      The current share price of Inozyme Pharma is $ 2.08
      How many Inozyme Pharma shares are in issue?
      Inozyme Pharma has 64,240,198 shares in issue
      What is the market cap of Inozyme Pharma?
      The market capitalisation of Inozyme Pharma is USD 179.87M
      What is the 1 year trading range for Inozyme Pharma share price?
      Inozyme Pharma has traded in the range of $ 1.98 to $ 7.795 during the past year
      What is the PE ratio of Inozyme Pharma?
      The price to earnings ratio of Inozyme Pharma is -1.81
      What is the reporting currency for Inozyme Pharma?
      Inozyme Pharma reports financial results in USD
      What is the latest annual profit for Inozyme Pharma?
      The latest annual profit of Inozyme Pharma is USD -71.17M
      What is the registered address of Inozyme Pharma?
      The registered address for Inozyme Pharma is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
      What is the Inozyme Pharma website address?
      The website address for Inozyme Pharma is www.inozyme.com
      Which industry sector does Inozyme Pharma operate in?
      Inozyme Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      VRMEVerifyMe Inc
      $ 2.57
      (52.98%)
      		57.83M
      WKEYWISeKey International Holdings AG
      $ 10.041
      (52.83%)
      		6.72M
      DATSDatChat Inc
      $ 4.8105
      (49.86%)
      		158.65M
      CDTConduit Pharmaceuticals Inc
      $ 0.1214
      (48.05%)
      		1.17B
      INTZIntrusion Inc
      $ 2.8888
      (44.44%)
      		40.61M
      IGMSIGM Biosciences Inc
      $ 2.095
      (-66.21%)
      		5.81M
      CDTGCDT Environmental Technology Investment Holdings Ltd
      $ 1.87
      (-51.30%)
      		2.28M
      MODVModivCare Inc
      $ 6.51
      (-47.88%)
      		2.73M
      AIFUAIX Inc
      $ 0.420501
      (-47.76%)
      		7.85M
      MRSNMersana Therapeutics Inc
      $ 0.691
      (-46.85%)
      		58.44M
      CDTConduit Pharmaceuticals Inc
      $ 0.1214
      (48.05%)
      		1.16B
      NVDANVIDIA Corporation
      $ 135.91
      (-3.00%)
      		203.27M
      RGTIRigetti Computing Inc
      $ 8.9299
      (-11.06%)
      		175.21M
      VMARVision Marine Technologies Inc
      $ 2.14
      (40.79%)
      		174.99M
      DATSDatChat Inc
      $ 4.8105
      (49.86%)
      		158.56M

      INZY Discussion

      View Posts
      tj9938 tj9938 2 months ago
      Taking a beating this week. 
      👍️0
      Monksdream Monksdream 4 months ago
      INZY under $6
      👍️0
      AJ Freely AJ Freely 1 year ago
      $INZY - 👆Up 7% Pre-Market/ Current Price $5.12
      Pivotal bioVenture Partners Fund I, L.P purchases
      835k shares equal to $4m investment
      👍️0
      Monksdream Monksdream 1 year ago
      INZY new 52 week high
      👍️0
      INFINITI INFINITI 2 years ago
      Loading
      👍️0
      Jess070283 Jess070283 2 years ago
      Have a feeling this about to squeeze into a halt soon…..
      👍️0
      tj9938 tj9938 2 years ago
      Great week so far. Gotta keep it movin.
      👍️0
      tj9938 tj9938 2 years ago
      Quietest board out there
      👍️0
      ErnieBilco ErnieBilco 3 years ago
      Grabbed a starter here today
      👍️0
      crudeoil24 crudeoil24 3 years ago
      INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

      (i) Deep Track Capital, LP

      (ii) Deep Track Biotechnology Master Fund, Ltd.

      (iii) David Kroin

      INZY
      👍️0
      tw0122 tw0122 3 years ago
      I like the BioXc chart looks better. Thanks for all the good insight.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      The offering is expected to close on or about April 19, 2022
      👍️0
      tw0122 tw0122 3 years ago
      This analyst know about the offering?
      Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      PT > 33.00
      👍️0
      crudeoil24 crudeoil24 3 years ago
      H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
      👍️0

      Your Recent History

      NASDAQ
      INZY
      Inozyme Pharma
      BIT
      CLI
      Central Del Latte Di Tor...
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads